After two decades in cancer therapy research, Clay Siegall’s Seattle Genetics has developed drugs that have brought relief to cancer patients and their families. However, the scientist journey started much earlier than 1998 when he founded the company. As a young adult studying zoology at the University of Maryland, Dr. Siegall saw the effects of the disease on its victim firsthand. This is after one of his relatives was diagnosed with cancer. In the next five years, he observed the ineffectiveness of the standard treatment procedure. Clay was convinced that various treatment procedures such as amputations were brutal and made a cancer patient weaker. This experience caused him to change his life goals to start finding humane treatments for cancer.
According to the Seattle Genetics’ founder and chief executive officer, the company took a very long period before it started generating revenues. However, the potential in antibody drug conjugate technology that the company was exploring saw it secure over $1.2 billion in funding. Presently, the company does not rely on funding from investors. The entity’s first cancer therapy, ADCetris, has been doing well in the market and is helping the company rake in millions of dollars in revenues. The FDA-approved drug is available to patients in over 60 countries globally. Moreover, the company earns revenues from licensing its technologies and processes. This situation helps Seattle Genetics to generate revenue while at the same time accelerating the development of better cancer therapies.
When asked about his successes, Dr. Siegall responded by saying that the answer lies on one’s work habit. He refers to a letter written by Charles Darwin, which said that human beings do not substantially differ in intellect. What makes the difference is the work habit. The executive leader adds that he is passionate about his career and tends to be workaholic.
About Clay Siegall
Dr. Clay Siegall is a celebrated expert in development of targeted cancer therapies. The CEO of Seattle Genetics has extensive experience in developing antibody drug conjugate therapies. He is a graduate of both the University of Maryland and George Washington University.
Before founding Seattle Genetics, he was working for different institutions such as the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research institute. Dr. Clay Siegall sits on the boards of Fred Hutchinson Cancer Research Center, Mirna Therapeutics, and Alder Biopharmaceuticals.